Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.

Trial Details

NCT ID
NCT06545942
Phase
PHASE1
Sponsor
MOMA Therapeutics
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • MOMA-313
  • Olaparib
Locations (sample)
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • La Jolla, California, United States|32.84727,-117.2742
  • San Francisco, California, United States|37.77493,-122.41942
  • Lake Mary, Florida, United States|28.75888,-81.31784
  • St Louis, Missouri, United States|38.62727,-90.19789

Key Eligibility Criteria

  • Age ≥ 18 years
  • Have histologically confirmed disease for each treatment arm as follows:
  • Treatment Arm 1 (MOMA-313 Monotherapy)
  • \- Advanced (including locally), relapsed or metastatic solid tumors that are not eligible for curative therapy, with any HR-deficient alteration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →